Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY 1753011 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | BAY1753011 30mg in addition to standard of care (SoC) for part A and part B |
| Arm 2 | PLACEBO_COMPARATOR | Placebo of BAY1753011 in addition to SoC for part A and part B |
| Arm 1-A | EXPERIMENTAL | BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B |
| Arm 1-B | ACTIVE_COMPARATOR | Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B |
| Arm 2-A | EXPERIMENTAL | BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B |
| Arm 2-B | ACTIVE_COMPARATOR | Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B |
| Name | Type | Description |
|---|---|---|
| BAY 1753011 | DRUG | Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral |
| Placebo BAY 1753011 | OTHER | Tablet; Once daily in the morning; Oral |
| Furosemide | DRUG | Tablet; 40mg unit; 80mg once daily in the morning; Oral |
| Placebo Furosemide | OTHER | Tablet; Once daily in the morning; Oral |
Inclusion Criteria: * History of CHF on individually optimized treatment with HF medications unless contraindicated or not tolerated, for at least 12 weeks prior to index hospitalization and in accordance with international guidelines. * Subjects admitted to the hospital with a primary diagnosis of...
Top 20 of 31 competitors
BAY 1753011 is an investigational small molecule being developed for the treatment of Heart Failure (HF). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with congestive heart failure.
BAY 1753011 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for heart failure.
BAY 1753011 is currently in Phase 2 clinical development. It is an investigational drug and has not received regulatory approval. The Phase 2 trial for BAY 1753011 has been completed, and the drug is being evaluated for the treatment of Heart Failure (HF).
BAY 1753011 has one completed Phase 2 clinical trial registered under NCT03901729, titled "A Trial to Study BAY1753011 in Patients With Congestive Heart Failure." This randomized, double-blind, placebo-controlled trial enrolled 482 participants across multiple countries including Austria, Bulgaria, Greece, Hungary, Israel, Italy, Poland, Portugal, and Spain.
No, BAY 1753011 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of Heart Failure (HF). The drug has not completed the clinical trial process required for regulatory approval and remains under investigation by Bayer AG.